Latest Blogs

Guest Commentary
Nov 28, 2023
Women Mentoring Women: A Thank You Note to My Two Heroes
Dr. Tara Rajendran honors two women who, through their kindness and thoughtful attention, shaped her professional path from an early age.
Linda R. Duska, MD, MPH
Nov 20, 2023
The Potential of AI in Clinical Research
"We all need to stay informed and engaged on the topic of AI in order to be the best advocates for ourselves, our profession, and our patients."
International Perspectives
Nov 03, 2023
Cancer, Conflict, and Catastrophe: A Cry for Help From Sudan, a Country at War
Millions of people have been affected by the war in Sudan, and the outlook for patients with cancer is particularly dire. Dr. Nabeeha Karadawi, Dr. Salma Awad Elkareem Ali Mohamed, and Nagham Ali outline the current situation and call for immediate international aid.
Abdul-Rahman Jazieh, MD, MPH
Oct 24, 2023
Should Oncologists Continue to Be Ambivalent About Dietary Supplement Use by Their Patients?
If we believe that dietary supplements are active compounds—and many are—then we should deal with them as medications and advise our patients accordingly.
Subscribe to this column

Clifford A. Hudis, MD, FASCO, FACP

Clifford A. Hudis, MD, FACP, FASCO, is the CEO of ASCO, executive vice chair of Conquer Cancer, the ASCO Foundation, and chair of CancerLinQ. Prior to these roles, he served as chief of the Breast Medicine Service and an attending physician at Memorial Sloan Kettering Cancer Center and as a professor in the Department of Medicine at Weill Cornell Medical College. He is a past president of ASCO. His research interests include all areas of care related to breast cancer, with a focus on the development of novel systemic therapies and prevention interventions related to obesity and inflammation. Follow Dr. Hudis on Twitter @CliffordHudis.

Disclosure.

Jul 16, 2018
Increasing Patient Inclusion in Cancer Clinical Trials: A Conversation With Dr. Edward S. Kim
Broadening eligibility critera for cancer clinical trials will give more patients the opportunity to contribute to scientific research.
Jul 09, 2018
Right-to-Try: A Conversation With Dr. Richard L. Schilsky
I am really pleased to have with us ASCO's Chief Medical Officer and Senior Vice President for a conversation focusing on right-to-try policies.
Jun 29, 2018
Highlights of May/June Board of Directors Meeting: Annual Meeting, Leadership Development Program
At the most recent Board of Directors meeting, we heard insightful presentations from participants in the Leadership Development Program, pivoted toward the execution of our 5-year strategic plan, and had a valuable conversation with NCI director Dr. Norman Sharpless.
2 Comments
May 24, 2018
Biosimilars: A Conversation With Dr. Gary H. Lyman
While more biosimilars will likely be available in oncology in the next several years, their specific impact on patient care is going to depend on patient and provider acceptance of these agents.
May 17, 2018
Changes to MOC: New Pathways for Assessment
ASCO would like to inform you of some changes to MOC that are a direct result of your input and our open, transparent collaboration with the ABIM. 
May 08, 2018
State Advocacy: A Conversation With Dr. Melissa S. Dillmon
We examine how state-level health care policy may impact the care that we deliver to our patients with cancer, and why it's important for us to pay attention to and help shape bills and regulations moving in states.

Pages